Onesource Specialty Pharma peers

Companies like Onesource Specialty Pharmalatest year

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ONESOURCE₹1,569.60

Onesource Specialty Pharma Ltd.

· Pharma & Health
₹ CrorePeersSTARDIVISLABGLANDPFIZERPOLYMEDRAINBOWKIMSJUBLPHARMAMcap ₹17,991 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
ONESOURCE
FY26
STAR
FY26
DIVISLAB
FY26
GLAND
FY26
Peer
Average
Valuation — at last close
P/E—◆ 18.19×99.89×49.31×55.80×
P/B◆ 3.09×3.26×15.28×4.89×7.81× -60%
EV/EBITDA62.99×◆ 12.55×73.43×29.17×38.39× +64%
Market Cap₹17,991 Cr₹10,116 Cr₹2.56L Cr₹50,655 Cr₹1.06L Cr -83%
Growth
Revenue CAGR 3Y—9.62%10.78%◆ 21.06%13.82%
Revenue CAGR 5Y—7.94%8.67%◆ 13.18%9.93%
Net Income CAGR 3Y——◆ 12.09%9.57%10.83%
Revenue YoY (latest Q)◆ 37.39%17.11%27.80%19.57%21.49% +74%
Net Income YoY (latest Q)◆ 448.25%1.97%65.50%47.09%38.19% +1074%
Profitability
EBITDA Margin21.40%19.04%◆ 32.59%25.34%25.66% -17%
Net Income Margin-5.19%11.82%◆ 24.32%15.98%17.37% -130%
Return on Common Equity-1.26%◆ 19.66%16.19%10.53%15.46% -108%
Return on Capital Employed0.38%◆ 19.31%17.80%11.73%16.28% -98%
Return on Assets-0.94%8.86%◆ 13.89%8.66%10.47% -109%
Credit & Quality
Total Debt/Equity0.22×0.53×◆ 0.00×0.02×0.18× +20%
Interest Coverage0.21×4.05×◆ 129.48×36.24×56.59× -100%
Scale — latest FY
Revenue / Total Income₹1,422 Cr₹4,859 Cr₹10,560 Cr₹6,431 Cr₹7,283 Cr -80%
Net Income−₹73.8 Cr₹575 Cr₹2,568 Cr₹1,027 Cr₹1,390 Cr -105%
Total Assets₹8,210 Cr₹6,927 Cr₹20,033 Cr₹12,511 Cr₹13,157 Cr -38%
EPS₹-6.44₹60.34₹96.75₹62.35₹73.15 -109%
Book Value per Share₹508.75₹337.14₹632.49₹628.67₹532.77 -5%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.